Latest Breaking News On - Neuropathic corneal pain - Page 1 : comparemela.com

OKYO Pharma Bullish Thesis - Insider Monkey

OKYO Pharma Bullish Thesis - Insider Monkey
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Dry eye diseaseNeuropathic corneal pain

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP)

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomGarys jacobPedram hamrahPaul spencerTranslational ocular immunology at tufts medical centerTufts medical centerDrug administrationCompany phasePharma limitedCornea servicePrincipal investigatorInvestigational new drugNeuropathic corneal painVice chairAcademic programs

OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, told investors it has filed an Investigational New Drug (IND) application with the US Food.

Pedram hamrahGary jacobTufts medical centerDrug administrationOkyo pharma ltdCornea serviceTranslational ocular immunology at tufts medical centerInvestigational new drugNeuropathic corneal painAcademic programsTranslational ocular immunologyTufts medicalAdvisory board

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

LONDON and NEW YORK, May 03, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet. | May 3, 2023

United kingdomSan diegoUnited statesCity ofPaul spencerRobert emmetGarys jacobPedram hamrahPharma limitedCornea serviceOptiva securitiesAmerican society of cataractLondon stock exchangeAmerican societyRefractive surgeryTranslational ocular immunology

OKYO Pharma to address key conference with data on dry eye drug

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), an ophthalmology-focused biopharmaceutical company, will showcase two presentations on its dry eye disease (DED).

United statesSan diegoPedram hamrahAmerican society of cataractEngland eye center at tufts medicalOkyo pharma ltdCornea serviceAmerican societyRefractive surgeryTranslational ocular immunologyNew england eye centerTufts medicalNeuropathic corneal pain